Dyadic International, Inc.
DYAIHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dyadic International, Inc. focuses on Biotechnology services and products. Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. Valued at $20.8M, DYAI is a micro-cap name in its sector. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Market Cap
$20.8M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-1.63
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.32
ROE
—
ROA
-63.0%
Cash
$3.1M
Total Debt
$5.0M
Free CF
-$4.8M
52W Change
-46.9%
Annual Financials
Cash vs Debt
Where DYAI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DYAI finished 38.10% below its 150-day moving average ($0.84) and 39.53% below its 200-day moving average ($0.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DYAI overbought or oversold?
At the September 3, 2026 close, DYAI's RSI(14) was 6.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, DYAI has $3.1M in cash with $5.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$4.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has pulled back from $2.9M (2022) to $1.2M (2025), a 58% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Dyadic International, Inc. and its sector.